










doi:10.101EBMT Risk Score Predicts Outcome of Allogeneic
Hematopoietic Stem Cell Transplantation in Patients
Who Have Failed a Previous Transplantation Procedure
Katayoun Rezvani, Edward J. Kanfer, David Marin, Ian Gabriel, Amin Rahemtulla,
Alexandra Taylor, Donald MacDonald, Francesco Dazzi, Dragana Milojkovic, Letizia Foroni,
Jiri Pavlu, Jeremy Sargent, Rifca Le Dieu, John M. Goldman, Jane Apperley, Richard SzydloIncreasing numbers of allogeneic hematopoietic stem cell transplantation (allo-SCT) are being performed for
patients who have failed a previous allogeneic or autologous SCT. We investigated whether the EBMT risk
score could predict outcome after a subsequent allo-SCT.We analyzed prognostic factors in 124 consecutive
patients who underwent a second transplantation using an allogeneic donor at our institution. Patients with
either a first autologous (N 5 64) or first allogeneic (N 5 60) SCTwere included. Age, disease stage, time
interval from diagnosis to transplantation, donor type, and donor–recipient sex combination were used to
establish a score from 0 to 7 points, from which 3 groups were identified. The 5-year survival probability
decreased from 51.7% for risk scores 0-3 (low, n 5 25), to 29.3% for risk score 4 (intermediate, n 5 42),
and only 10.4% for risk scores 5-7 (high, n5 57), P5.001. We propose that the EBMTrisk score can identify
patients most likely to benefit from a second transplantation.
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LymphomaINTRODUCTION for patients with chronic myeloid leukemia (CML),Relapse is the most frequent cause of treatment
failure after allogeneic (allo-) or autologous (auto-)
hematopoietic stem cell transplantation (SCT). Sev-
eral studies have shown that a subsequent allo-SCT
procedure may be an effective salvage intervention
with a probability of disease-free survival (DFS) rang-
ing from 11% to 44%, and relapse rates of 25% to 75%
[1-14]. Given that relapse after transplantation has
a dismal prognosis, and that selected patients can
remain alive and disease-free after a subsequent allo-
SCT, identification of prognostic factors that deter-
mine more reliably the patient group most likely to
benefit would be valuable.
In 1998, the European Group for Blood and
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6/j.bbmt.2011.06.010the most frequent indication for an allo-SCT at that
time [15]. The risk score was based on 5 criteria: dis-
ease stage, patient age, donor type, interval from diag-
nosis to transplantation, and donor–recipient sex
combination. The score was validated in several
independent CML patient cohorts as well as for other
hematologic malignancies [16].
Here we investigated the prognostic value of the
EBMT risk score to predict the outcome of subsequent
allo-SCT in patients with hematologic malignancies
who have failed a first transplantation. We demon-
strated that the five well-defined pretransplantation
patient and donor characteristics that make up the
EBMT risk score, together with the interval between
first and second SCT, are independent predictors of
nonrelapse mortality (NRM) and overall survival (OS).MATERIALS AND METHODS
Patient Population
We performed a retrospective analysis of the out-
comes of transplantation in 124 consecutive patients
who underwent a second SCT using an allogeneic do-
nor between October 1985 and July 2010, after prior
allogeneic (n 5 60) or autologous (n 5 64) SCT. All235
236 Biol Blood Marrow Transplant 18:235-240, 2012K. Rezvani et al.patients gave written informed consent for the use of
their data for the analysis.
EBMT Risk Score
The EBMT risk score was calculated based on
5 pretransplantation variables: age of the patient, dis-
ease stage, time from diagnosis to transplantation, do-
nor type, and donor–recipient sex combination, with 0,
1, or 2 points for each factor [15]. Age was categorized
as\20 years (0), 20 to 40 years (1), and .40 years (2).
The stage of disease applied to our patient population
at the time of second SCTwas as follows: Early disease
stage (0) was limited to patients with CML who had
relapsed after a prior auto- or allo-SCT and remained
in chronic phase. All other patients were, by definition,
scored as intermediate- or late-stage disease. Interme-
diate disease stage (1) included: acute leukemia in
second complete remission CML in all other stages
than chronic phase or blast crisis myelodysplastic syn-
drome (MDS) in second complete remission or in par-
tial remission; and non-Hodgkin lymphoma (NHL)
and multiple myeloma in second complete remission,
in partial remission, or stable disease. Late-stage dis-
ease (2) included: acute leukemia in all other disease
stages, CML in blast crisis, MDS in all other disease
stages, and multiple myeloma and lymphoma in all
other disease stages than those defined as early or in-
termediate. Time from first diagnosis to second trans-
plant was categorized into\12 months (0) and .12
months (1). Donor type separated HLA-identical sib-
ling transplants (0) from unrelated donor transplants
and mismatched family donors (1). Donor–recipient
sex combination separated all others (0) from the
male recipient with a female donor (1). Hence, the
score ranged from 0 to a maximum of 7 risk points.
Statistical Analysis
Two outcomes were considered: OS and NRM.
Probability curves were calculated using the Kaplan-
Meier method for survival and the cumulative inci-
dence procedure for NRM. Outcomes were calculated
relative to the date of second transplantation, until the
event of interest, or until the date of last follow-up.
Groupswere compared using the log-rank test, and fac-
tors found to be significant at the P\ .1 level were en-
tered into a Cox regression analysis. All analyses were
performed using SPSS version 17 software (SPSS,
Inc., Chicago, IL). All statistical tests were 2 sided,
and P\ .05 was used to indicate statistical significance.RESULTS
Patient Characteristics
The patient characteristics are summarized in
Table 1. The median interval between first and secondSCT was 20 months. Patients were more likely to have
a longer interval to second SCT if they had a diagnosis
of CML (38 of 57) compared with patients with acute
leukemia and MDS (11 of 25), myeloma (7 of 22), or
NHL (7 of 17) (P 5 .038). At second SCT, donors
wereHLA-identical siblings (n5 66, 53.2%), matched
unrelated donors (n 5 41, 33.1%), mismatched unre-
lated donors (n 5 8, 6.5%), and nonidentical family
donors (n 5 9, 7.2%). The source of the graft was pe-
ripheral blood stem cells (PBSC) (n 5 60, 48.4%) and
bone marrow (BM) (n 5 64, 51.6%). Of 61 patients
who relapsed following a previous allo-SCT, 41 re-
ceived stem cells from the same donor, 13 from a differ-
ent donor, and in 7 this information was not available.
Conditioning intensity was classified into reduced
intensity (RIC) (n 5 52; 41.9%) or myeloablative
(MAC) (n 5 72; 58.1%). In 37 of 52 (71%) patients
who received an RIC second transplant, the prepara-
tive regimen was fludarabine based (in combination
with cyclophosphamide, busulphan, or melphalan).
Of 72 patients who received an MAC conditioned
transplant, 29 (40%) received total body irridiation
(TBI) (1320 or 1400 cGy), and in 28 (39%) the prepar-
ative regimen was busulphan based (16 mg/kg orally).
In vivo T cell depletion with alemtuzumab was used in
83 of 124 recipients (66.9%). At the time of the analy-
sis, 29 of 124 patients were alive (23.4%), and 95 had
died (76.6%) (73 from transplant-related causes and
22 of their disease). Transplant-related causes of mor-
tality included infection in 41, graft-versus-host dis-
ease (GVHD) in 8, graft failure in 3, and other
transplant-related causes including veno-occlusive dis-
ease (VOD), pneumonitis, acute respiratory distress
syndrome (ARDS), and multiorgan failure in 21 pa-
tients. Median survival was 9.6 months. For the entire
group, the probability of survival at 5 years was 25.4%
(95% confidence interval [CI]: 18%-34%) with an es-
timated cumulative incidence of NRM at 1 year of
45.0% (95% CI: 37%-55%).EBMT Risk Score at Second SCT
TheEBMT score was calculated for each patient at
second SCT, based on the factors outlined above
(Table 2). EBMT risk scores of 0 to 7 points were
assigned to each patient, and because of low numbers
of patients with some scores, 3 combined groups
were identified (Table 2B).
The survival probability at 5 years decreased from
51.7% (95% CI: 33%-70%) for risk scores 0-3 (low,
n 5 25), to 29.3% (95% CI: 17%-47%) for risk score
4 (intermediate, n 5 40), and only 10.4% (95% CI:
4%-24%) for risk scores 5-7 (high, n 5 57), P 5
.0003 (Figure 1A), whereas 1-year NRM rates in-
creased from 28.03% (95% CI: 15-53; risk score, 0-
3) to 33.2% (95% CI: 21-52; risk score, 4) and
58.8% (95% CI: 47-73; risk score, 5-7), P 5 .0003
Table 1. Patient Characteristics and Relative Risk Impact of Pretransplantation Risk Factors on Survival
Patient Characteristics at Second SCT N (%)
Probability of NRM
at 1 Year (95% CI) P Value*
Probability of Survival
at 5 Years (95% CI) P Value*
Indication for Second SCT .066 .18
CML-CP1 9 (7.3) 11.1 (2-71) 64.8 (15-51)
CML-Adv 48 (38.7) 35.4 (24-52) 33.1 (23-56)
ALL 5 (4.0) — —
AML/MDS 20 (16.1) 55.6 (37-83) 14.6 (4-39)
Myeloma 22 (17.7) 54.6 (33-76) 9.1 (3-27)
NHL 17 (13.7) 61.9 (42-92) 40.3 (21-63)
Other 3 (2.4) — —
First SCT .094 .056
Auto 64 (51.6) 49.5 (39-64) 16.3 (8-31)
Allo 60 (48.4) 40.3 (30-55) 33.7 (23-46)
Disease stage .008 .019
Early 9 (7.3%) 10.0 (2-64) 57.1 (28-82)
Intermediate 53 (42.7) 40.7 (30-57) 33.2 (21-48)
Advanced 62 (50.0) 54.1 (43-68) 12.5 (6-24)
Age (years) .007 .016
<20 4 (3.2) 50.0 (5-100) 25.0 (5-67)
20-40 62 (50.0) 35.8 (26-50) 36.7 (26-49)
>40 58 (46.8) 54.6 (43-69) 12.4 (6-25)
Duration of disease pre-SCT (months) .11 .38
<12 9 (7.3) 66.7 (42-100) 16.7 (3-53)
>12 115 (92.7) 43.3 (35-53) 26.1 (20-34)
Donor match .88 .70
HLA-id.sib. 75 (60.5) 44.1 (34-57) 25.8 (19-35)
Other 49 (59.5) 46.6 (34-63) 25.4 (17-37)
Patient/donor sex .92 .87
M/F 22 (17.7) 46.0 (29-73) 29.8 (15-51)
Other 100 (82.3) 43.7 (35-55) 25.0 (17-36)
Interval between first and
second SCT (months)
.001 .005
<20 months 60 (48.4) 59.8 (48-74) 14.7 (7-27)
>20 months 63 (51.6) 30.3 (21-44) 34.7 (26-45)
Conditioning .13 .30
RIC 52 (41.9) 52.2 (40-68) 14.6 (7-27)
MA 72 (58.1) 40.3 (30-53) 34.7 (26-45)
Cells infused .066 .16
BM 64 (51.6) 37.5 (27-51) 31.1 (21-44)
PBSC 60 (48.4) 53.0 (42-68) 16.6 (8-31)
GVHD prophylaxis: T cell depletion .73 .75
Yes 83 (66.9) 45.2 (36-57) 25.7 (17-39)
No 41 (33.1) 44.7 (32-63) 25.3 (14-41)
GVHD indicates graft-versus-host disease; PBSC, peripheral blood stem cell; BM, bone marrow; RIC, reduced-intensity conditioning; SCT, stem cell
transplantation; NHL, non-Hodgkin lymphoma; ALL, acute lymphoblastic leukemia; AML, acute myelogeneous leukemia; MDS, myelodysplastic
syndrome; CML, chronic myeloid leukemia; NRM, nonrelapse mortality; CI, confidence interval.
*P values based on log-rank tests.
Biol Blood Marrow Transplant 18:235-240, 2012 237EBMT Risk Score and Second Transplant Outcome(Figure 1B). We found no significant difference in the
risk of acute GVHD (aGvHD) (grades 2-4) among the
3 risk score groups (33% vs 28% vs 27% respectively;
P 5 .87).
We also tested the prognostic influence of the
variables shown in Table 1. Univariate analyses
showed that the nature of the previous transplantation
(auto vs allo, P 5 .056), and interval between first and
second transplantation (\ or . the median of 20
months, P5 .005) were associated with survival, unlike
conditioning intensity (MAC vs RIC, P 5 .30), graft
(BM vs PBSC, P 5 .16), or the use of T cell depletion
(P5 .75). Patients were more likely to receive anMAC
at second SCT if they had a diagnosis of CML chronic
phase (CP) (8 of 9), CML accelerated phase (AP) (37 of
48), and acute myeloid leukemia/myyelodysplastic
syndrome (AML/MDS) (13 of 20) compared withonly 2 of 5 acute lymphoblastic leukemia (ALL), 5 of
22 myeloma, and 7 of 17 NHL patients (P\ .0001).
As expected, before year 2000 only 11 of 61 transplants
were reduced intensity compared with 41 of 63, after
year 2000; P\ .0001. Furthermore, we found no rela-
tionship between the type of first transplant (auto vs
allo) and the conditioning intensity at second SCT
(RIC vs MAC); P 5 .43.
In multivariate analysis, however, only two factors
were found to be important. An increased risk of death
was associated with an increasing risk score, relative
risk (RR) 2.83, high score (P 5 .001) and RR 1.75,
intermediate score (P 5 .09) when compared with
the low-score group and with a shorter interval be-
tween first and second SCT (\20 months), RR 1.59,
P5 .03. The same two variables were similarly signif-
icant in multivariate analysis of NRM (data not
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20-40 62 (50.0) 1
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(95% CI) P Value
EBMT score .0003 .0003
0-3 25 (20.2) 28.0 (15-53) 51.7 (33-70)
4 40 (32.3) 33.2 (21-52) 29.3 (17-46)
>4 57 (46.0) 58.8 (47-73) 10.4 (4-24)
SCT indicates stem cell transplantation; CI, confidence interval; EBMT,
European blood and marrow transplant; NRM, nonrelapse mortality.
Figure 1. Overall survival and nonrelapse mortality (NRM) of 124
patients undergoing allo-SCT after prior allogeneic or autologous SCT
for an acquired hematologic disorder is shown by risk score. Graphs
reflect probabilities of 5-year overall survival (A), 1 year NRM (B), and
the combinatorial effect of risk score and interval between first and sec-
ond SCT (C). RS indicates risk score; m, month.
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that is, risk score and interval between first and second
SCT, were combined, we found that patients who
had a low-risk score or who were in the intermediate
risk group but were .20 months after their first
SCT (N 5 48) had a significantly improved 5-year
OS compared with patients who had a high-risk score
or who were in the intermediate-risk group but were
\20 months after their first SCT (N 5 73); namely,
48.5% versus 9.1% (P 5 .00006) (Figure 1C).DISCUSSION
Options to treat relapse after transplantation in-
clude the choice of no further therapy, withdrawal of
immunosuppression to elicit a graft-versus-tumor
(GVT) response, chemotherapy, donor lymphocyte
infusions, and second transplantations [17]. A recent
evidence-based guideline published by the American
Society of Hematology has given the use of second al-
logeneic transplantation after relapse a recommenda-
tion score of 1B [18]. The current challenge is to
identify patients who may benefit from a second allo-
SCT procedure. A number of studies (all retrospective)
have evaluated the role of second allo-SCT [19-30].Despite the heterogeneity of these studies, it appears
that patients with chemo-sensitive disease in remis-
sion who had a long initial remission after first trans-
plantation are those who benefit most after a second
transplantation.
The EBMT risk score was first described in the
1990s to predict outcome of allo-SCT in patients
with CML [15]. The value of this score was then
confirmed by several independent series and extended
to all patients with hematologic malignancies treated
with allo-SCT [16]. Our study is the first to investigate
the prognostic value of the EBMT risk score on
outcomes of second allo-SCT for patients who have
failed a previous auto- or allo-SCT. We show that
the five well-defined pretransplantation patient and
donor characteristics, namely, age, stage of the disease,
Biol Blood Marrow Transplant 18:235-240, 2012 239EBMT Risk Score and Second Transplant Outcometime interval from diagnosis to transplantation, donor
type, and donor–recipient sex combination, can give
valuable predictive information on transplant-related
mortality (TRM) and survival for an individual patient
at the time of second SCT. Prediction is further im-
proved by taking into account the duration of remis-
sion after the first transplantation procedure. We
propose that the EBMT risk score together with the
interval between first and second SCTs can provide
an accurate estimate of outcome and help in the selec-
tion of patients most likely to benefit from a second
transplantation.
In our study, we found no other factors to have
a significant impact on OS, although on univariate
analysis, there was a trend for inferior survival in
patients who received an auto-SCT for their first
transplantation compared with those who relapsed af-
ter an allo-SCT. This difference in outcome is likely to
be related to the inclusion of patients with more ad-
vanced disease, including relapsed multiple myeloma
and high-grade NHL, in the autograft group. Indeed
the impact of the first transplantation on OS was no
longer significant when disease stage was considered
as part of the multivariate analysis.
This study has a number of limitations. Owing to
the retrospective nature of the study, it is probable
that significant inherent selection biases exist. As
anticipated for the study period, CMLwas the indica-
tion for second SCT in a significant proportion of
patients, which may limit the applicability of the
analysis to the current era. Patients were more likely
to receive anMAC at the second SCT if they had a di-
agnosis of CML or AML/MDS compared with pa-
tients with ALL, myeloma, or NHL, who were
more likely to receive an RIC (P\ .0001). Nonethe-
less, we found no impact of conditioning intensity or
transplantation era on outcome (data not shown).
The majority of patients received stem cells from
the original donors in this study; it remains to be de-
termined if using an alternative donor for the second
procedure offers an advantage.
We conclude that that the option to treat relapse
after transplantation with a second transplantation
should be based on risk assessment. We suggest that
taking into account both the interval between first
and second SCTs and the five well-defined pretrans-
plantation patient and donor characteristics that
make up the EBMT risk score can provide an accurate
estimate of outcome and help in the selection of
patients most likely to benefit from a second trans-
plantation. Based on this study, we conclude that
a subsequent allo-SCT has an important potential
role in treating relapse after failing allo- or auto-
SCT in patients with low-risk score or intermediate
score with late relapse after their first SCT. Patients
with high-risk scores or intermediate scores with
early relapse are unlikely to benefit from a secondtransplantation. These results should be validated in
a larger cohort of patients.ACKNOWLEDGMENTS
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